Details der Publikation - Dalbavancin in clinical practice: a particular place for the elderly?

Dalbavancin in clinical practice: a particular place for the elderly?

Abstract We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin’s administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients..

Medienart:	Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:41
Enthalten in:	European journal of clinical microbiology & infectious diseases - 41(2022), 6 vom: 26. Apr., Seite 977-979

Sprache:	Englisch

Beteiligte Personen:	Wackenheim, Chloé [VerfasserIn] Le Maréchal, Marion [VerfasserIn] Pluchart, Hélène [VerfasserIn] Gavazzi, Gaëtan [VerfasserIn] Blanc, Myriam [VerfasserIn] Caspar, Yvan [VerfasserIn] Pavese, Patricia [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Aged Anti-bacterial agents Arthritis Bone diseases, infectious Comorbidity

RVK:	RVK Klassifikation ELIB24 ELIB09

Anmerkungen:	© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

doi:	10.1007/s10096-022-04427-2

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2078778834

Internformat


LEADER	01000caa a22002652 4500
001	OLC2078778834
003	DE-627
005	20230510125901.0
007	tu
008	221220s2022 xx \|\|\|\|\| 00\| \|\|eng c
024	7		\|a 10.1007/s10096-022-04427-2 \|2 doi
035			\|a (DE-627)OLC2078778834
035			\|a (DE-He213)s10096-022-04427-2-p
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a ELIB24 \|q VZ \|2 rvk
084			\|a ELIB09 \|q VZ \|2 rvk
100	1		\|a Wackenheim, Chloé \|e verfasserin \|4 aut
245	1	0	\|a Dalbavancin in clinical practice: a particular place for the elderly?
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a ohne Hilfsmittel zu benutzen \|b n \|2 rdamedia
338			\|a Band \|b nc \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022
520			\|a Abstract We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin’s administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients.
650		4	\|a Aged
650		4	\|a Anti-bacterial agents
650		4	\|a Arthritis
650		4	\|a Bone diseases, infectious
650		4	\|a Comorbidity
700	1		\|a Le Maréchal, Marion \|4 aut
700	1		\|a Pluchart, Hélène \|4 aut
700	1		\|a Gavazzi, Gaëtan \|4 aut
700	1		\|a Blanc, Myriam \|4 aut
700	1		\|a Caspar, Yvan \|4 aut
700	1		\|a Pavese, Patricia \|4 aut
773	0	8	\|i Enthalten in \|t European journal of clinical microbiology & infectious diseases \|d Springer Berlin Heidelberg, 1982 \|g 41(2022), 6 vom: 26. Apr., Seite 977-979 \|h Online-Ressource \|w (DE-627)25372273X \|w (DE-600)1459049-9 \|w (DE-576)072372575 \|x 1435-4373 \|7 nnns
773	1	8	\|g volume:41 \|g year:2022 \|g number:6 \|g day:26 \|g month:04 \|g pages:977-979
856	4	1	\|u https://doi.org/10.1007/s10096-022-04427-2 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a SSG-OLC-PHA
912			\|a SSG-OLC-DE-84
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
936	r	v	\|a ELIB09
951			\|a AR
952			\|d 41 \|j 2022 \|e 6 \|b 26 \|c 04 \|h 977-979

Dalbavancin in clinical practice: a particular place for the elderly?

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände